Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor

Jae Heon Jeong, Byoung Chul Cho, Hyo Sup Shim, Hye Ryun Kim, Sun Min Lim, Se Kyu Kim, Kyung Young Chung, S. M. Bakhtiar Ul Islam, Jae Jin Song, Soo Youl Kim, Joo Hang Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-B). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-B expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-B expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-B value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinumbased doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P = 0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P = 0.013). Similarly, in EGFR wild-type patients treatedwith EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P = 0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI

Original languageEnglish
Pages (from-to)1005-1014
Number of pages10
JournalJournal of Korean medical science
Volume28
Issue number7
DOIs
Publication statusPublished - 2013 Jul

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Disease-Free Survival
NF-kappa B
transglutaminase 2
Drug Therapy
Adjuvant Chemotherapy
Platinum
Drug Resistance
Adenocarcinoma
Therapeutics
Enzymes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Jeong, Jae Heon ; Cho, Byoung Chul ; Shim, Hyo Sup ; Kim, Hye Ryun ; Lim, Sun Min ; Kim, Se Kyu ; Chung, Kyung Young ; Bakhtiar Ul Islam, S. M. ; Song, Jae Jin ; Kim, Soo Youl ; Kim, Joo Hang. / Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor. In: Journal of Korean medical science. 2013 ; Vol. 28, No. 7. pp. 1005-1014.
@article{34d78f6e2c844c53822c43ea41cecd26,
title = "Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor",
abstract = "Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-B). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-B expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-B expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-B value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinumbased doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P = 0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P = 0.013). Similarly, in EGFR wild-type patients treatedwith EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P = 0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI",
author = "Jeong, {Jae Heon} and Cho, {Byoung Chul} and Shim, {Hyo Sup} and Kim, {Hye Ryun} and Lim, {Sun Min} and Kim, {Se Kyu} and Chung, {Kyung Young} and {Bakhtiar Ul Islam}, {S. M.} and Song, {Jae Jin} and Kim, {Soo Youl} and Kim, {Joo Hang}",
year = "2013",
month = "7",
doi = "10.3346/jkms.2013.28.7.1005",
language = "English",
volume = "28",
pages = "1005--1014",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "7",

}

Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor. / Jeong, Jae Heon; Cho, Byoung Chul; Shim, Hyo Sup; Kim, Hye Ryun; Lim, Sun Min; Kim, Se Kyu; Chung, Kyung Young; Bakhtiar Ul Islam, S. M.; Song, Jae Jin; Kim, Soo Youl; Kim, Joo Hang.

In: Journal of Korean medical science, Vol. 28, No. 7, 07.2013, p. 1005-1014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor

AU - Jeong, Jae Heon

AU - Cho, Byoung Chul

AU - Shim, Hyo Sup

AU - Kim, Hye Ryun

AU - Lim, Sun Min

AU - Kim, Se Kyu

AU - Chung, Kyung Young

AU - Bakhtiar Ul Islam, S. M.

AU - Song, Jae Jin

AU - Kim, Soo Youl

AU - Kim, Joo Hang

PY - 2013/7

Y1 - 2013/7

N2 - Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-B). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-B expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-B expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-B value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinumbased doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P = 0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P = 0.013). Similarly, in EGFR wild-type patients treatedwith EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P = 0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI

AB - Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-B). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-B expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-B expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-B value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinumbased doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P = 0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P = 0.013). Similarly, in EGFR wild-type patients treatedwith EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P = 0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI

UR - http://www.scopus.com/inward/record.url?scp=84880717979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880717979&partnerID=8YFLogxK

U2 - 10.3346/jkms.2013.28.7.1005

DO - 10.3346/jkms.2013.28.7.1005

M3 - Article

C2 - 23853482

AN - SCOPUS:84880717979

VL - 28

SP - 1005

EP - 1014

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 7

ER -